NASDAQ: ACRV - Acrivon Therapeutics, Inc.

Rentabilité sur six mois: -2.63%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Acrivon Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

plus de détails
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2022-11-15
ISIN US0048901096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.acrivon.com
Цена ао 6.33
Changement de prix par jour: -4.36% (6.19)
Changement de prix par semaine: -11.77% (6.71)
Changement de prix par mois: -21.28% (7.52)
Changement de prix sur 3 mois: -17.32% (7.16)
Changement de prix sur six mois: -2.63% (6.08)
Changement de prix par an: +20.33% (4.92)
Evolution du prix sur 3 ans: 0% (5.92)
Evolution du prix sur 5 ans: 0% (5.92)
Evolution des prix sur 10 ans: 0% (5.92)
Evolution des prix depuis le début de l'année: -30.92% (8.57)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.9109 9
P/E 0 0
EV/EBITDA -1.18 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % -43.68 0
ROE, % -49.83 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0696 10
Total: 9.2

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 1770.38 10
Rentabilité EPS, % 564.2 10
Total: 8
Plus de détails

Établissements Volume Partager, %
RA Capital Management, L.P. 4810508 21.25
Perceptive Advisors LLC 3007858 13.29
Sands Capital Ventures, LLC 1652605 7.3
Citadel Advisors Llc 1649659 7.29
Wellington Management Group, LLP 888130 3.92
Marshall Wace LLP 597469 2.64
Blackrock Inc. 565832 2.5
Vanguard Group Inc 475977 2.1
NEA Management Company, LLC 430252 1.9
Federated Hermes, Inc. 226375 1

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Range Cancer Therapeutics ETF 2.03779 47.24 0.11955
iShares Micro-Cap ETF 0.02284 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00853 27.77 1.68271
Schwab U.S. Small-Cap ETF 0.00415 17.47 1.51433
ProShares UltraPro Russell2000 0.0019 89.82 1.47873
ProShares Hedge Replication ETF 0.00053 5.92 1.47892
Schwab U.S. Broad Market ETF 0.00053 24.86 1.43354
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer 977.7k 1963 (62 année)
Ms. Kristina Masson M.B.A., Ph.D. Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director 739.78k 1981 (44 année)
Mr. Rasmus Holm-Jorgensen Chief Financial Officer 1M 1972 (53 année)
Dr. Eric J. Devroe Ph.D. Chief Operating Officer 614.78k 1979 (46 années)
Ms. Katharine Peterson CPA Vice President of Finance & Accounting N/A
Dr. Adam D. Levy M.B.A., Ph.D. Senior VP and Head of Investor Relations & Corporate Affairs N/A
Mr. Bruce Close Vice President of Quality & Compliance N/A
Ms. Mary-Alice Miller J.D. Chief Legal Officer 587.11k 1974 (51 année)
Ms. Parvin Miah VP & Head of Human Resources N/A
Dr. Erick Gamelin M.D., Ph.D. Chief Development Officer 480.72k 1958 (67 années)

Adresse: United States, Watertown. MA, 480 Arsenal Way - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.acrivon.com